The specific killing effect of matrine on castration-resistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway
Authors: Xiaoli Yu
Yiming Lai
Ting Chen
Shoumin Bai
Hai Huang
Ming Luo
Xianju Chen
Chunhao Lin
Journal: Oncology Reports (2017)
Discipline: CLINICAL MEDICINE
Keywords: Matrine; LY294002; Akt/FoxO3a signaling pathway; proliferation; castration-resistant prostate cancer
Affiliations: Department of Radiation Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, P.R. China., Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, P.R. China.

Abstract:  Matrine, a Sophora alkaloid, exhibits antiproliferative and anti-carcinogenic activities through several mechanisms. In a previous study, we found that matrine could effectively inhibit the proliferation of castration-resistant prostate cancer (CRPC). In the present study, the effect of matrine and LY294002 on the expression of the Akt/FoxO3a signaling pathway was examined by western blot analyses and RT-PCR. We discovered that matrine significantly inhibited the proliferation of both prostate cancer cell line PC-3 and prostate epithelial cell line RWPE1, induced apoptosis and induced cell cycle arrest. In addition, LY294002 was found to enhance the effect of matrine. Furthermore, the effects of matrine on the inhibition of proliferation and the induction of cell cycle arrest and cell apoptosis were more effective on PC-3 than on RWPE1 cells. Compared to RWPE1 cells, matrine exerted a more powerful influence on PC-3 cells in increasing the expression of the relevant protein. Our data suggested that FoxO3a-Bim and FoxO3a-P27 may mediate matrine-inhibited proliferation of CRPC cells by activating cell apoptosis and inducing cell cycle arrest. Matrine exhibited high selectivity in killing CRPC cells. Our findings demonstrated that matrine could be used in a potential therapeutic role in the management of CRPC in humans. 

Retracted: No

PubPeer comments:
 Figure 4. * Blue boxes: The PC-3 LY294002 panel looks unexpectedly similar to the RWPE1 control panel. ![file] , 
 Corrigendum, September 2020: https: www.spandidos-publications.com 10.3892 or.2020.7784  Subsequently to the publication of the article, the authors have realized that some errors were contained therein that went uncorrected before the paper was sent to press. First, Fig. 4 contained a pair of data panels that had been misplaced: The LY294002, PC-3 data panel in Fig. 4A showed the same data as the RWPE-1, control panel in Fig. 4B, and the LY294002, RWPE-1 data panel showed the same data as the matrine, control panel in Fig. 4B. These errors arose inadvertently during the process of re-organizing the layout of the figure; a corrected version of Fig. 4, showing the correct data panels for the LY294002, PC-3 and LY294002, RWPE-1 experiments in Fig. 4A and B respectively, is shown on the next page. Also note that the data shown in Fig. 4C and E have been re-calculated on the basis of the correction of the data in this Figure, and the revised histograms are also shown in these Figure parts. In view of these corrections, in the u201cMatrine induces cell apoptosis by increasing Bim and Bax and decreasing Bcl-2 protein levels in prostate cancer cell linesu201d subsection of the Results section towards the bottom of p. 2822, in the penultimate sentence, the text u201c...LY294002 resulted in 25.88% cell apoptosis in the PC-3 cells and 18.88% in the RWPE1 cells, compared to 3.11 and 6.89%, respectively, with LY294002 treatment only (Fig. 4A-D).u201d should be corrected to: u201c...LY294002 resulted in 25.88% cell apoptosis in the PC-3 cells and 18.88% in the RWPE1 cells, compared to 10.94% and 6.89%, respectively, with LY294002 treatment only (Fig. 4A-D).u201d (the changed datum is shown in bold). Note that the corrected data shown in Fig. 4, and the revision made to the Results section, do not affect the overall conclusions reported in the paper. The authors thank the Editor of Oncology Reports for allowing them the opportunity to present this Corrigendum, and apologize and to the readership for any inconvenience caused. I thank the authors and journal for correcting this figure. ,